Now, the cell that this scientist obtained day to use technology of Cheng of a revolutionary new-model to arise treats the license of heart disease patient. This research is inductivity merely much abler (IPS) the 2nd of the cell clinical application. The cell that IPS cell organizes by the body such as skin of revulsive such as, blood is reductive found to similar and embryonic condition, and can become other cell kind from embryonic position development.
Recently, deep unripe work saves Japan allow the doctor is collected originate a particularly small shape tissue of IPS cell, transplant its to go up to the human heart that produces pathological change. This group that heads by Yoshiki Sawa of surgeon of Osaka university heart shows, be damaged when the organ (the heart disease symptom that spot piece is accumulated or the heart attack causes) when, these the organization can help an account organic muscle second birth.
"This will cause global attention, because a lot of groups are devoting oneself to the research of this direction. " Thomas Eschenhagen of director of cardiovascular research center represents pharmacologist of German hamburger university, this state.
Will have 3 people next year preliminary accept this treatment. Subsequently, sawa group will be sought win the approval that begins clinical trial in about 10 patients. If be confirmed to be safe, this therapeutics will undertake commercializing selling below the swift passage system in medicine of Japanese second birth.
This system that introduced 2014, aim to enhance a likelihood to save the usability of the medical flow of life. But the person that criticize thinks, this system is put in blemish, because it allows remedial method,can provide a patient before the enough data that confirms flow get the desired result is collected.
In newest therapeutics, sawa and colleague used IPS cell to found an amount to amount to 100 million cardiac muscle cell. This group considers to confirm through what begin on pig body, these cellular layers (every thick 0.1 millimeter, 4 centimeters long) transplanting can improve organic function to the heart.
Sawa expresses, these cells appear won't integrated in heart tissue. He thinks, contrary, they released reborn of help damage muscle to grow factor.
The scientist expresses, an advantage of layer of this kind of cell depended on founding the cellular matrix of oneself, and need not be made by foreign material become " scaffold " can keep its structure, and the feature that this is organization of a few other projects.
"This is a kind of extremely simple, clever cell carries a method. " é of Philippe Menasch of surgeon of heart of Pi Du hospital expresses Qiao Zhipeng of French Paris Europe. He creates similar organ layer in the attempt all the time.
Wolfram-Hubertus Zimmermann of pharmacologist of center of medicine of university of root of elder brother the court of a feudal ruler is developing the IPS treatment that is aimed at heart disease likewise. He thinks, afore-mentioned newest experiments are be in with Sawa and its work in the same placing go 15 years a work that begin be a foundation.
Once Sawa group cures 3 patients, its develop application a clinical trial that involves 7~10 person. If this therapeutics is confirmed to be safe, and show the sign of a few be successful, so it will win batch of sales through swift passage system.
This allows researcher to bypass the costly large and clinical trial that aims to confirm curative effect, using miniature forerunner experiment to confirm this therapeutics is safe and show a curative effect.
Nevertheless, a few researcher think, approve doorsill of commercial of this kind of therapeutics too low. The cell that even if produces is discovered to be safe, still exist with the risk related any surgical operations.
In the meantime, the patient may abandon other treatment, and turn to a kind probably cannot the therapeutics of be successful. Ethnics home expresses with the person that superintend, the benefit of any new treatment must exceed a risk.
Look in Yoshiki Yui of home of Kyoto university cardiology, besides accord with security demand, researcher still ought to confirm their therapeutics is effective, and this need develops a test in more large-scale crowd.
In the meantime. Evaluate a process to ought to use random clinical contrast experiment. In medical research, this is the gold standard that confirms curative effect.
Yui thinks, newest IPS cell therapeutics is put in latent capacity, but the system is examined and approve to fall in what have, "We do not know whether it is met be successful " , because it will not be in,contrast the test gets in the experiment. "The biggest question is Japan does not have proper assessment system. " Yui expresses.
Deep unripe work saves a spokesman to express, showing some to examine and approve a system is complete, because researcher still must confirm some kind of therapeutics is effective, its already obtained even if approve business to use.
Sawa thinks likewise, contrast the group is very main to confirming therapeutics. But he expresses, oneself abided by Japanese regulation, do not need to begin before business of a kind of therapy is used namely contrast experiment.
Look in Sawa, door of Ministry of Public Health approved this treatment, admit it namely " looking to accept a test in the patient from the angle of science and ethics is proper " . "Its whether true be successful, we must find the solution now. " Sawa says.
" Chinese science signs up for " (2018-06-06 international of the 3rd edition)
